CXCL9 and central nervous system cancer: In gliomas, the IDH1 mutation has a negative impact on the immune system resulting in reduced Natural Killer ligands and decreased tumor lysis, as well as decreased chemokines CXCL9, CXCL10 with subsequent reduction in the number of CD3+ CD8+ tumor infiltrating lymphocytes (63, 64).